Novo Nordisk | NVO - Current Liabilities


Novo Nordisk reported DKK32.79B in Current Liabilities for its fiscal quarter ending in June of 2025.





Current Liabilities Change Date
ANI Pharmaceuticals USD 270.56M 33.72M Sep/2025
Aurora Cannabis CAD 124.12M 32.76M Sep/2025
Bausch Health Companies USD 4.18B 613M Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Canopy Growth CAD 81.1M 17.56M Sep/2025
Corcept Therapeutics USD 172.26M 27.6M Sep/2025
Drreddys Laboratories INR 1.76B 62.5M Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Novartis USD 32B 286M Sep/2025
Novo Nordisk DKK 215.66B 18.7B Dec/2025
Novo Nordisk DKK 32.79B 203.33B Jun/2025
Pacira USD 107.08M 206.09M Sep/2025
Perrigo USD 1.15B 19.2M Sep/2025
Phibro Animal Health USD 282.37M 12.23M Dec/2025
Prestige Brands USD 139.56M 4.95M Dec/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Supernus Pharmaceuticals USD 330.63M 44.27M Sep/2025
Zoetis USD 2.24B 428M Dec/2025